GLP-1 Diarrhea: How Common It Is

Diarrhea on a GLP-1 medicine is listed in the adverse reactions table of each of the five labels reviewed here, and it was more frequent than on placebo in every one. It affected between 8.5% and 30% of trial participants on the medicine, depending on the product, dose and trial. The labels give how often diarrhea happens, not how long one episode lasts, so the dates of your dose steps are the clue worth watching. Signs of dehydration need a doctor.

In short

• The Wegovy label reports diarrhea in 30% of adults on 2.4 mg against 16% on placebo in weight management trials.
• The Zepbound label reports 19%, 21% and 23% at 5, 10 and 15 mg against 8% on placebo.
• The Ozempic and Mounjaro labels link diarrhea with dehydration and acute kidney injury in some postmarketing cases.

How common is diarrhea on a GLP-1 medication?

Diarrhea was reported by 8.5% to 30% of people on a GLP-1 medicine in the placebo-controlled trials behind each prescribing label. The table below uses each label's own adverse reactions table for the indication that label studied.

Populations and durations differ. The Ozempic label pools two 30-week trials (mean exposure 32.9 weeks). The Rybelsus label averages 41.8 weeks. The Mounjaro label pools SURPASS-1 and SURPASS-5 (36.6 weeks). The Wegovy label covers three trials of up to 68 weeks. The Zepbound label pools two 72-week trials and counts frequent bowel movements as diarrhea.

Subtracting placebo gives the gap: 14 points for Wegovy (30 minus 16), 15 for Zepbound at 15 mg (23 minus 8), 8 for Mounjaro at 15 mg (17 minus 9). Placebo rates differ between trials, so the tables do not rank the medicines against each other.

Why do GLP-1 medications cause diarrhea?

The labels list diarrhea as an adverse reaction, but their tables do not show its cause. They count how often it occurred, drug against placebo, and say nothing about why one person is affected and another is not.

Two things the tables do show. First, diarrhea also occurs without the medicine: placebo groups reported it in 1.9% to 16% of participants, depending on the trial. Second, the tirzepatide tables show higher rates at higher doses, from 12% to 17% on Mounjaro and 19% to 23% on Zepbound.

Those numbers describe groups of people, not a mechanism. The tables cannot say whether the rise with dose reflects how much medicine is active or something else, so this guide does not claim to know.

When does GLP-1 diarrhea start and how long does it last?

The labels do not state how many days one episode of diarrhea lasts, so no label-based duration can be given. They report how many participants had diarrhea at any point over the whole trial, which cannot show a start day or an end day.

One timing clue exists, and it covers gastrointestinal reactions as a group. The Zepbound label reports discontinuation because of GI adverse reactions of 0.5% on placebo, 1.9% at 5 mg, 3.3% at 10 mg and 4.3% at 15 mg, and says most occurred in the first few months. That points to early onset of GI reactions as a group, not diarrhea specifically.

Your own record fills the gap the labels leave. Note the date of each dose and the days you had loose stools. To see how long a semaglutide dose stays active, read our guide on how long Ozempic stays in your system. The free GLP-1 half-life calculator estimates how much semaglutide or tirzepatide is still active after a shot. It is an estimate, not a lab value.

Does diarrhea come back after a dose increase?

The labels do not say how often diarrhea returns after a dose increase, because their tables compare separate dose groups and do not follow one person through each step. What the tirzepatide tables show is a higher diarrhea rate at each higher dose. Our guide on how long Mounjaro takes to work explains how each dose builds up.

The Ozempic and Mounjaro labels also advise monitoring kidney function during initiation and dose escalation. They report postmarketing kidney injury mostly in patients whose GI reactions, including diarrhea, led to dehydration.

Any change in dose is the prescriber's decision, never a response to loose stools made alone.

What helps with GLP-1 diarrhea?

The labels' kidney warnings make fluid loss the main thing to guard against, and they leave other measures to your prescriber. The Ozempic, Wegovy, Mounjaro and Zepbound labels all link diarrhea with dehydration and kidney injury.

• Keep fluids up. The Zepbound label attributes most postmarketing kidney injury cases to nausea, vomiting or diarrhea causing dehydration.
• Eat lighter. Small, lower-fat meals are covered in our guide to what to eat on Ozempic shot day, with USDA figures.
• Log each day. Writing down stool changes and dose dates gives your prescriber a pattern instead of a memory.
• Ask before using an anti-diarrheal. The labels cited here do not address them, so check with a pharmacist or prescriber first.
• Call your prescriber if it does not ease. Persistent diarrhea is a reason to ask, and only they can decide about the dose.

When does diarrhea mean it's time to call a doctor?

Diarrhea needs a doctor when it is severe, persistent, bloody or paired with signs of dehydration. The labels tie diarrhea to dehydration and acute kidney injury, which makes these signs worth acting on.

• Severe or persistent diarrhea that does not ease
• Blood in the stool
• Severe abdominal pain
• Common signs of dehydration, such as dizziness, dark urine, a rapid heartbeat, little urine or being unable to keep fluids down

Seek emergency care for severe symptoms. Kidney injury was uncommon in the trials but is a labeled risk. The Wegovy label reports acute kidney injury in 7 patients (0.4 per 100 patient-years) against 4 on placebo (0.2), some linked to GI reactions or dehydration. The Zepbound label reports 0.5% against 0.2% on placebo.

Where can you log diarrhea next to your doses?

Dose & Lose is a tracking app that lets you rate side effects from 0 to 10 each day and see them over time next to your logged doses. That can show whether loose stools line up with a dose date.

It does not diagnose, treat or advise on diarrhea, and it does not give dosing advice. Its job is a clear record to show your prescriber. Read more at Dose & Lose.

Frequently asked questions

Is it safe to take an anti-diarrheal like loperamide on a GLP-1?

Ask your pharmacist or prescriber before taking one. The label sections cited in this guide do not address anti-diarrheals, so they give no basis for a yes or no. Blood in the stool, severe pain or signs of dehydration need a doctor rather than self-treatment.

Can diarrhea mean the dose is too high?

Only your prescriber can judge that. The Mounjaro and Zepbound labels report more diarrhea at higher doses, but the tables compare groups, not one person. Do not lower, skip or stop a dose because of loose stools. Tell your prescriber and bring your log.

Does diarrhea mean the medication is working?

The label tables give no basis for reading diarrhea as a sign of effect. They list it as an adverse reaction, counted against placebo, and the trials measured effect separately. Judge results by the measures your prescriber uses, and tell them about persistent loose stools.

Can diet changes alone stop GLP-1 diarrhea?

The sources in this guide do not test food changes, so no label figure supports a promise. Lighter meals and steady fluids are covered in our shot-day food guide. If diarrhea persists, or any warning sign appears, call your prescriber instead of relying on diet alone.

Sources

Published by Petros IT Solutions SRL, byline Dose & Lose Editorial Team. Corrections: office@doseandlose.com.

• Ozempic prescribing information: diarrhea by dose, kidney warning.
• Wegovy prescribing information: weight trial diarrhea, kidney injury.
• Mounjaro prescribing information: diarrhea by dose.
• Zepbound prescribing information: diarrhea by dose, discontinuation, kidney injury.
• Rybelsus prescribing information: oral semaglutide diarrhea.